A major pooled analysis published in JAMA has shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors deliver consistent ...

In a retrospective study, repetitive transcranial magnetic stimulation produces weight loss comparable to semaglutide 0.5 ...

ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today ...

A recent review examined how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may ...

And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide ...

At the 2025 AMCP annual meeting in Houston, John M. O'Brien, Pharm.D., M.P.H., president and CEO of the National ...

A normal echocardiogram doesn't always mean a healthy heart. Persistent symptoms like breathlessness and fatigue can indicate ...

With rates of juvenile type 2 diabetes rocketing in the US, doctors now have access to an alternative oral therapy – the first new oral option for more than 20 years. Eli Lilly and Boehringer ...

Meanwhile, in attempts to address long-standing thyroid cancer concerns, a research team conducted a 350,000-person analysis ...

Diabetes medications found to influence cancer growth in unexpected ways What if the drugs millions take for diabetes every ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly-priced new contender. The FDA approved Steglatro (ertugliflozin) as a monotherapy in conjunction with diet and exercise ...